Wikisage, the free encyclopedia of the second generation, is digital heritage

Doripenem: Difference between revisions

From Wikisage
Jump to navigation Jump to search
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 5: Line 5:
<ref>https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022106s012lbl.pdf</ref>
<ref>https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022106s012lbl.pdf</ref>
||
||
[[d:Q411552]]
{{wikidata|Q411552}}
|}
|}


==ATC==
==ATC==
<ref>[https://karmel.miraheze.org/m/6Sy karnmel(miraheze) es:Doripenem]</ref>
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5
|colspan=2| <center>
[[File:Doripenem_vert1.jpg|292px]]
: [[wikipedia:doripenem|doripenem]]
<ref>[https://www.whocc.no/atc_ddd_index/?code=J01DH04 J01DH04]</ref></center>
|}
<ref>[https://karmel.miraheze.org/m/6Sy karmel(miraheze) es:Doripenem]</ref>


{{refs}}
{{refs}}

Latest revision as of 21:28, 2 September 2021

Doripenem is a beta-lactam antibiotic agent belonging to the carbapenem group

Seizures have been reported during treatment with doripenem (see section 6.2). In clinical trials, doripenem-treated patients with pre-existing central nervous system (CNS) disorders (e.g. stroke or history of seizures), patients with compromised renal function and patients given doses greater than 500 mg every 8 hours appear to be at greater risk for developing seizures [1]

Q411552 at Wikidata  Interwiki via Wikidata

ATC

doripenem
[2]

[3]

References

References: